158 related articles for article (PubMed ID: 23370422)
1. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.
Vekeman F; Cloutier M; Yermakov S; Amonkar MM; Arondekar B; Duh MS
Melanoma Res; 2014 Dec; 24(6):602-10. PubMed ID: 24926818
[TBL] [Abstract][Full Text] [Related]
5. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
Copher R; Cerulli A; Watkins A; Laura Monsalvo M
J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Montero AJ; Eapen S; Gorin B; Adler P
Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
[TBL] [Abstract][Full Text] [Related]
9. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
10. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
12. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
13. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.
Ivanova JI; Birnbaum HG; Schiller M; Kantor E; Johnstone BM; Swindle RW
Spine J; 2011 Jul; 11(7):622-32. PubMed ID: 21601533
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
16. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.
Ekwueme DU; Guy GP; Li C; Rim SH; Parelkar P; Chen SC
J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S133-43. PubMed ID: 22018062
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs and nonadherence among chronic opioid users.
Leider HL; Dhaliwal J; Davis EJ; Kulakodlu M; Buikema AR
Am J Manag Care; 2011 Jan; 17(1):32-40. PubMed ID: 21348566
[TBL] [Abstract][Full Text] [Related]
19. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
[No Abstract] [Full Text] [Related]
20. Comparative healthcare costs in patients with metastatic melanoma in the USA.
Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
